Article

Safety and efficacy of inhaled mannitol in patients with cystic fibrosis: Metanalysis

2025-03-05

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Cystic fibrosis is a multi-system autosomal recessive disorder with considerable mortality and morbidity associated with respiratory manifestations. Due to thick, viscous mucus production, which causes airway obstruction and subsequent respiratory infections, multiple drugs are being used to clear the secretions. Inhaled mannitol is one treatment regime that acts by increasing...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 235f3be4-21c8-57a6-bb47-65f8c596a15d
DOI: 10.1101/2025.03.02.25323206

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Safety and efficacy of inhaled mannitol in patients with cystic fibrosis: MetanalysisDOI 10.1101/2025.03.02.25323206Read

Treating the Airway Consequences of Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction.Semantic proximity Read

Review of CFTR modulators 2020.Semantic proximity Read

Cystic fibrosis year in review 2020: Section 2 pulmonary disease, infections, and inflammation.Semantic proximity Read

Real-world data on the efficacy and safety of tezacaftor-ivacaftor in adults living with cystic fibrosis homozygous for F508del and heterozygous for F508del and a residual function mutation.Semantic proximity Read

Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.Semantic proximity Read

Ivacaftor in cystic fibrosis with residual function: Lung function results from an N-of-1 study.Semantic proximity Read

Systematic review of nasal endoscopy scores in cystic fibrosis patients treated with CFTR modulatorsSemantic proximity Read

Effects of Lumacaftor-Ivacaftor on Lung Clearance Index, Magnetic Resonance Imaging, and Airway Microbiome in Phe508del Homozygous Patients with Cystic Fibrosis.Semantic proximity Read

Standards for the care of people with cystic fibrosis; establishing and maintaining health.Semantic proximity Read

Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial.Semantic proximity Read

Trikafta therapy alters the CF lung mucus metabolome reshaping microbiome niche spaceSemantic proximity Read

Effects of elexacaftor-tezacaftor-ivacaftor on daily treatment burden and airflow obstruction in adults with cystic fibrosis.Semantic proximity Read